Ładuje się......
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
IMPORTANCE: When a novel drug is granted accelerated approval, both its on-label and off-label uses must be taken into account. OBJECTIVES: To estimate the potential upper bound of off-label use of erdafitinib to treat advanced cancer with fibroblast growth factor receptor gene (FGFR) alterations, c...
Zapisane w:
| Wydane w: | JAMA Netw Open |
|---|---|
| Główni autorzy: | , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
American Medical Association
2019
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6902826/ https://ncbi.nlm.nih.gov/pubmed/31755953 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.16091 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|